{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:58:56Z","timestamp":1765915136616,"version":"3.48.0"},"reference-count":25,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prescription drug insurance in Canada is constituted of a patchwork of public and private insurance plans. The type of drug insurance may have a negative impact on access to treatment for patients covered by public plans compared with private plans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objectives\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>In patients with psoriasis treated with advanced therapy in public vs private drug insurance groups, we compared: (1) psoriasis severity scores when an advanced therapy was prescribed, (2) psoriasis severity scores at follow-up, (3) treatment response, and (4) delay between prescription and first dose of advanced therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This unicentric, retrospective cohort study included patients suffering from psoriasis treated by advanced therapy, dermatologist-prescribed between September 2015 and August 2019, in a tertiary academic care center in Qu\u00e9bec City, Canada. Data were collected from medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients treated with an advanced therapy for psoriasis covered under the provincial public drug insurance plan (n\u2009=\u200978) and under a private drug plan (n\u2009=\u200993) did not differ regarding the studied outcomes. Patients\u2019 characteristics differed between groups. Patients in the public group were older (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001), more socioeconomically deprived (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.05), and more likely to benefit from compassion from the industry to access a prescribed medication free of charge (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001) compared with patients from the privately insured group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"discussion\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The high prevalence of compassionate programs from the industry in the public insurance group (42% vs 14%), and the high prevalence of psoriasis on difficult-to-treat areas (face, genitalia, and\/or palmoplantar areas) in our cohort (85.4%) may mask differences in access to advanced therapy between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prescribers of advanced therapy can be reassured, as we found no inequality in access or care based on patients\u2019 drug insurance coverage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.127820","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T10:13:40Z","timestamp":1738923220000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":0,"title":["Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study"],"prefix":"10.36469","volume":"12","author":[{"given":"Laurence","family":"Mainville","sequence":"first","affiliation":[{"name":"Department of Medicine, CHU de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec, Canada","department":["Division of Dermatology"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Veillette","sequence":"additional","affiliation":[{"name":"Department of Medicine, CHU de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec, Canada","department":["Division of Dermatology"]},{"name":"Department of Medicine, CHU de Qu\u00e9bec-Universit\u00e9 Laval","department":["Medicine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Fortin","sequence":"additional","affiliation":[{"name":"Department of Medicine, CHU de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec, Canada","department":["Division of Rheumatology"]},{"name":"Centre de recherche du CHU de Qu\u00e9bec \u2013 Universit\u00e9 Laval"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22273","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7365937","DOI":"10.1155\/2017\/7365937","article-title":"Public versus private drug insurance and outcomes of patients requiring biologic therapies for inflammatory bowel disease","volume":"2017","author":"A. Rumman","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"2","key":"ref2","first-page":"119","article-title":"Clearance of psoriasis: the impact of private versus public insurance","volume":"14","author":"C. D. Buzney","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"ref3","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1080\/03007995.2016.1227775","article-title":"Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006-2009","volume":"32","author":"M. Cifaldi","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"ref4","first-page":"982","article-title":"The relationship between insurance class and severity of presentation of inflammatory bowel disease in children","volume":"90","author":"W. Spivak","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"suppl 2","key":"ref5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","article-title":"What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature","volume":"24","author":"E. Puzenat","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"ref6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"A. Y. Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"ref7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1365-2133.2008.08832.x","article-title":"The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results","volume":"159","author":"M. K. Basra","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"R. G. Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"J. Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"ref10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.24095\/hpcdp.29.4.05","article-title":"A deprivation index for health planning in Canada","volume":"29","author":"R. Pampalon","year":"2009","journal-title":"Chronic Dis Can"},{"issue":"4","key":"ref11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2310\/7750.2011.10066","article-title":"Canadian guidelines for the management of plaque psoriasis: overview","volume":"15","author":"K. Papp","year":"2011","journal-title":"J Cutan Med Surg"},{"article-title":"The Challenges of Updating the Deprivation Index with Data from the 2011 Census and the National Household Survey (NHS)","year":"2017","author":"P. Gamache","key":"ref12"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","article-title":"Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study","volume":"80","author":"C. Paul","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2040622319843756","DOI":"10.1177\/2040622319843756","article-title":"Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement","volume":"10","author":"T. Y. Ger","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"edition":"2","article-title":"Epidemiology: An Introduction","year":"2012","key":"ref15"},{"issue":"12","key":"ref16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1111\/j.1468-3083.2010.03663.x","article-title":"Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands","volume":"24","author":"K. A. Meeuwis","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"ref17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0190-9622(03)02793-2","article-title":"Facial psoriasis: comparison of patients with and without facial involvement","volume":"50","author":"J. Young Park","year":"2004","journal-title":"J Am Acad Dermatol"},{"article-title":"Modification d\u2019une indication reconnue\u2013M\u00e9dicament d\u2019exception\u2013Avec conditions : Apremilast","year":"2020","author":"INESSS","key":"ref18"},{"key":"ref19","first-page":"9","article-title":"Modification d\u2019une indication reconnue\u2013M\u00e9dicament d\u2019exception\u2013Avec conditions: Sekukinumab, Etanercept, Adalimumab, Infliximab, Brodalumab, Ustekinumab, Ixekizumab, Risankizumab, and Guselkumab","author":"INESSS","year":"2020"},{"issue":"5","key":"ref20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/j.1365-2133.2008.08512.x","article-title":"Evaluation of the reimbursement criteria for biological therapies for psoriasis in the Netherlands","volume":"158","author":"M. Wakkee","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"ref21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10067-009-1338-1","article-title":"Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy","volume":"29","author":"A. S. Russell","year":"2010","journal-title":"Clin Rheumatol"},{"year":"2020","key":"ref22","article-title":"Extrait de l\u2019avis au ministre sur Cimzia (psoriasis plaques)"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/jdv.13452","article-title":"Barriers to guideline-compliant psoriasis care: analyses and concepts","volume":"30","author":"L. Eissing","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"ref24","first-page":"2024","article-title":"Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis","volume":"34","author":"M. M. Ward","year":"2007","journal-title":"J Rheumatol"},{"issue":"6","key":"ref25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamadermatol.2013.133","article-title":"Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels","volume":"149","author":"T. Bhutani","year":"2013","journal-title":"JAMA Dermatol"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/127820-drug-insurance-and-psoriasis-severity-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:54:12Z","timestamp":1765914852000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/127820-drug-insurance-and-psoriasis-severity-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.127820","relation":{},"ISSN":["2327-2236"],"issn-type":[{"type":"electronic","value":"2327-2236"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}